/ Pre-IPO Risk Index / Neuralink

Neuralink

Medical Device · Pre-IPO · $5B (Q3 2023, secondary 2024)
D

High Risk (D) — Round Z Pre-IPO Risk Grade

Neuralink develops implantable brain-computer interfaces. FDA Investigational Device Exemption (IDE) trials began 2023-2024 with multiple human implants. Animal-welfare litigation, ongoing FDA oversight, and the founder's cross-investment structure with other Musk-controlled entities create material governance and regulatory complexity. Commercial path remains uncertain.

42
Composite / 100
/ Subscore Breakdown · 5 Dimensions

Where this grade comes from.

Governance Risk
D
Valuation Methodology
D
Secondary Liquidity
C
Financial Disclosure
D
Exit Probability
D+
/ Public-Record Events

Key risk events & disclosures.

  • First human implant January 2024
  • Multiple human implants 2024-2025
  • Animal-welfare lawsuits filed 2022-2024
  • FDA IDE oversight ongoing
  • Founder-controlled governance with cross-investments

/ Best for

Limited recommendation. Investors with very high conviction on long-term BCI category who can hold through extensive regulatory development timeline.

/ Watch out for

Commercial revenue path is 5-10+ years out. Animal-welfare litigation outcomes and FDA approval timelines are material risks not yet fully priced.